US tariff uncertainty on innovative medicines
Potential tariffs on patented drug imports into the US could impact Sun Pharma's innovative portfolio, though generics are expected to be excluded.
high · analyst_question
Sunpharma Ltd — Q2 FY26
Sun Pharma reported a solid Q2 FY26 with consolidated revenue of INR 14,405 crore (+8.6% YoY) and EBITDA of INR 4,527 crore (+14.9% YoY), with EBITDA margin expanding 170 bps Yo...
bullish
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Lenalidomide revenue decline
Lenalidomide sales have dropped YoY and are expected to be minimal in the second half, impacting US generics revenue.
medium · management_commentaryHigher effective tax rate normalization
ETR increased to 24.7% from 15.8% YoY due to expiry of tax benefits, expected to hover around 25%, pressuring net profit growth.
medium · management_commentaryCompetition in alopecia areata market
Stagnation in prescriptions for existing targeted treatments could hinder Leqselvi's uptake, though management expects market growth.
medium · analyst_question